Morgan Stanley’s Vincerx Pharma, Inc. Common Stock VINC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-102
| Closed | -$54 | – | 8391 |
|
|
2025
Q1 | $54 | Sell |
102
-3
| -3% | -$5 | ﹤0.01% | 7702 |
|
|
2024
Q4 | $549 | Buy |
105
+17
| +19% | +$112 | ﹤0.01% | 7335 |
|
|
2024
Q3 | $1.25K | Hold |
88
| – | – | ﹤0.01% | 7196 |
|
|
2024
Q2 | $1.42K | Sell |
88
-893
| -91% | -$22.4K | ﹤0.01% | 7114 |
|
|
2024
Q1 | $99.3K | Sell |
981
-795
| -45% | -$50.2K | ﹤0.01% | 5990 |
|
|
2023
Q4 | $41.9K | Buy |
1,776
+535
| +43% | +$8.99K | ﹤0.01% | 6437 |
|
|
2023
Q3 | $25.1K | Buy |
1,241
+34
| +3% | +$660 | ﹤0.01% | 6419 |
|
|
2023
Q2 | $31.4K | Hold |
1,207
| – | – | ﹤0.01% | 6391 |
|
|
2023
Q1 | $25.1K | Buy |
1,207
+72
| +6% | +$1.61K | ﹤0.01% | 6547 |
|
|
2022
Q4 | $23.2K | Sell |
1,135
-691
| -38% | -$13K | ﹤0.01% | 6626 |
|
|
2022
Q3 | $51K | Sell |
1,826
-737
| -29% | -$21.2K | ﹤0.01% | 6400 |
|
|
2022
Q2 | $69K | Buy |
2,563
+935
| +57% | +$41.6K | ﹤0.01% | 6461 |
|
|
2022
Q1 | $131K | Buy |
1,628
+86
| +6% | +$10.6K | ﹤0.01% | 6149 |
|
|
2021
Q4 | $314K | Sell |
1,542
-196
| -11% | -$48.9K | ﹤0.01% | 5816 |
|
|
2021
Q3 | $562K | Buy |
1,738
+122
| +8% | +$35.6K | ﹤0.01% | 5420 |
|
|
2021
Q2 | $419K | Buy |
1,616
+1,033
| +177% | +$315K | ﹤0.01% | 5634 |
|
|
2021
Q1 | $224K | Buy |
583
+477
| +450% | +$192K | ﹤0.01% | 5596 |
|
|
2020
Q4 | $44K | Buy |
+106
| New | +$33.4K | ﹤0.01% | 6198 |
|
Other funds holding VINC
Morgan Stanley's VINC Position: Q2 2025 in Review
Morgan Stanley sold out of Vincerx Pharma, Inc. Common Stock (VINC) in Q2 2025, closing a stake of 102 shares — an estimated $54 sold.
Morgan Stanley first reported a position in VINC in Q4 2020 and held it in 18 quarters. The position peaked at $562K in Q3 2021. 1 fund tracked by Wall St. Rank holds VINC as of Q2 2025.
- Morgan Stanley reported no remaining Vincerx Pharma, Inc. Common Stock position as of Q2 2025 after selling out during the quarter.
- Morgan Stanley sold 102 Vincerx Pharma, Inc. Common Stock shares in Q2 2025, an estimated $54.
- Morgan Stanley first reported a position in Vincerx Pharma, Inc. Common Stock in Q4 2020 and held it in 18 quarters.
- Morgan Stanley's Vincerx Pharma, Inc. Common Stock position peaked at $562K in Q3 2021.
- 1 fund tracked by Wall St. Rank held Vincerx Pharma, Inc. Common Stock as of Q2 2025.
Based on Morgan Stanley's 13F filing for Q2 2025, filed 15 Aug 2025.